OrbiMed Advisors

Latest statistics and disclosures from ORBIMED ADVISORS's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are Bacterin Intl Hldgs. These five stock positions account for 100.00% of ORBIMED ADVISORS's total stock portfolio.
  • Reduced shares in these 10 stocks: BMY (-$637.44M), Actavis (-$618.51M), (-$509.56M), AMGN (-$487.38M), CELG (-$365.67M), GILD (-$334.76M), (-$331.61M), (-$331.42M), Relypsa (-$319.49M), (-$317.68M).
  • Sold out of its positions in AMAG, ABT, Abbvie, ACHN, Advaxis, AET, AFFX, Agilent Technologies Inc C ommon, AKRX, ALXN.
  • As of June 30, 2015, ORBIMED ADVISORS has $1.66M in assets under management (AUM). Assets under management dropped from a total value of $11.71B to $1.66M.
  • Independent of market fluctuations, ORBIMED ADVISORS was a net seller by $11.71B worth of stocks in the most recent quarter.

ORBIMED ADVISORS portfolio companies for June 2015 quarter

Ticker Name Portfolio Weight Change Share Count Price Last Trade
Bacterin Intl Hldgs 100.00 475439 3.50 0.00

Past 13F-HR SEC Filings for ORBIMED ADVISORS

View All Filings for ORBIMED ADVISORS